The Clinical Evaluation of Deferasirox Effect on Hematological Parameters after Lead Administration

The Clinical Evaluation of Deferasirox Effect on Hematological Parameters after Lead Administration

Bibliographic Details
Main Authors:	Maliheh Zahmati, Amir Shokooh Saljooghi
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2016-12-01
Series:	Asia Pacific Journal of Medical Toxicology
Online Access:	http://apjmt.mums.ac.ir/article_8139_d41d8cd98f00b204e9800998ecf8427e.pdf

Similar Items

[(Pyridine-2,6-dicarboxylato)copper(II)]-&#956;-(pyridine-2,6-dicarboxylato)-[bis(ethylenediamine)copper(II)]-&#956;-(pyridine-2,6-dicarboxylato)-[(pyridine-2,6-dicarboxylato)copper(II)] ethylenediamine monosolvate tetrahydrate
by: Amir Shokooh Saljooghi, et al.
Published: (2012-06-01)

Long-term hematological response in 5q- syndrome after lenalidomide suspension and further improvement by deferasirox.
by: Pasquale Niscola
Published: (2014-08-01)

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
by: Andrea Piolatto, et al.
Published: (2021-06-01)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
by: Laura Galeotti, et al.
Published: (2021-08-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

A Study of Knowledge about Deferasirox and Behavior of Taking Deferasirox in Patients with β-Thalassemia Major
by: Pei-Yi Mei, et al.
Published: (2012)

Dianilinium bis(pyridine-2,6-dicarboxylato-&#954;3O2,N,O6)cuprate(II) hexahydrate
by: Amir Shokooh Saljooghi, et al.
Published: (2012-08-01)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
by: Giuseppe A. Palumbo, et al.
Published: (2021-10-01)

Deferasirox, an oral chelator in the treatment of iron overload
by: I. Portioli
Published: (2013-05-01)

Deferasirox – a rarer cause of Fanconi syndrome
by: Iman Khan, et al.
Published: (2019-07-01)

Pharmacogenetic study of deferasirox, an iron chelating agent.
by: Ji Won Lee, et al.
Published: (2013-01-01)

DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01)

Microalbuminuria in hemoglobinopathy patients who are taking Deferasirox
by: Asaad A Khalaf, et al.
Published: (2015-01-01)

Update on the use of deferasirox in the management of iron overload
by: Ali Taher, et al.
Published: (2009-10-01)

Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children
by: Asti Y. Rindarwati, et al.
Published: (2016-12-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Duran Canatan, et al.
Published: (2014-08-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

The Protective Effects of Deferasirox (DFX) in Hep G2 Cell
by: CHEN,JHEN-JYUN, et al.
Published: (2017)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
by: Nancy F Olivieri, et al.
Published: (2019-01-01)

The Effects of Lead Toxicity on the Hematological Parameters Common Carp (Cyprinus carpio) at Varying Salinity Levels
by: Zahra Tulaby Dezfuly, et al.
Published: (2020-01-01)

<b>Determination of trace amounts of zinc by flame atomic absorption spectrometry after separation and preconcentration onto modified natural analcime zeolite loaded 2,3,5,6-tetra(2-pyridyl)pyrazine</b>
by: A. Shokooh Saljooghi, et al.
Published: (2010-04-01)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
by: Hana Votavova, et al.
Published: (2021-01-01)

Deferasirox: appraisal of safety and efficacy in long-term therapy
by: Chaudhary P, et al.
Published: (2013-08-01)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
by: Chalmers AW, et al.
Published: (2016-02-01)

Clinical, Toxicological, Biochemical, and Hematologic Parameters in Lead Exposed Workers of a Car Battery Industry
by: Sina Kianoush, et al.
Published: (2013-03-01)

LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY
by: Ashraf Tawfik Soliman, et al.
Published: (2014-04-01)

Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia
by: Murtadha Al-Khabori, et al.
Published: (2013-03-01)

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase
by: Maryam Moradi, et al.
Published: (2014-11-01)

Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients
by: Shikha Jaiswal, et al.
Published: (2017-02-01)

ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR
by: Evy Sari Sutrisnaningsih, et al.
Published: (2017-08-01)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
by: Alba Rodríguez-García, et al.
Published: (2019-10-01)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
by: Trisha E. Wong, et al.
Published: (2021-09-01)

Effect of ketorolac administration post bone cavitation surgery on some hematological parameters
by: Raffal A. Omar
Published: (2017-06-01)

Deferasirox, an Iron-Chelating Agent, Improves Testicular Morphometric and Sperm Functional Parameters in a Rat Model of Varicocele
by: M. Rahmani, et al.
Published: (2021-01-01)

Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
by: Del Corso Lisette, et al.
Published: (2013-01-01)

Bioaccumulation of lead nitrate in tissues and its effects on hematological and biochemical parameters of Clarias gariepinus
by: Abdel-Wahab A. Abdel-Warith, et al.
Published: (2020-03-01)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015-12-01)

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
by: Elena Maria Elli, et al.
Published: (2014-05-01)

Risk of adverse events associated with deferasirox in patients using iron chelators
by: Hsin-Chun Chou, et al.
Published: (2012)

Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study
by: Hamidreza Badeli, et al.
Published: (2019-01-01)

Cannot write session to /tmp/vufind_sessions/sess_40vec4jkqgsgi7i6lhv233q2dk